Global Photodynamic Therapy Market

Wound care devices are used to prevent wound infections and promote wound healing. The main types of wound care devices are traditional adhesive dressings, negative-pressure wound therapy (NPWT), Traditional gauze dressings, and advanced wound care devices. Traditional wound dressing products including gauze, lint, plasters, bandages, and cotton wool are dry and used as primary or secondary dressings for protecting the wound from contaminations. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The wound care devices market research report is one of a series of new reports from The Business Research Company that provides wound care devices market statistics, including wound care devices industry global market size, regional shares, competitors with a wound care devices market share, detailed wound care devices market segments, market trends and opportunities, and any further data you may need to thrive in the wound care devices industry. This wound care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global wound care devices market grew from $55.05 billion in 2022 to $59.79 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The wound care devices market is expected to grow to $80.02 billion in 2027 at a CAGR of 7.6%. Combination dressings are increasingly being used to treat chronic wounds. The most widely used combination dressing is an antimicrobial agent and a biological material that together acts as a combination dressing. Combination dressings blend the chemical and physical properties of two or more types of wound dressing products to provide, waterproofing, anti-bacterial and viral infections, and skin-friendly capabilities. For instance, ConvaTec offers AQUACEL combination dressings that are made up of Hydrofiber Technology that incorporates offers stitch bonding functionality and increases the tensile strength of the dressing to be used as a combination dressing with an absorbent for the treatment of chronic wounds. Most widely used combination dressings include silver alginate dressings, silver collagen dressings, collagen hydrochloride dressings, and foam dressings. These dressings are used in the treatment of chronic ulcers, traumatic wounds, and surgical wounds. Wound care device manufacturers should consider focusing on delivering wound care products such as hydrocolloid dressings to improve treatment effectiveness and usage. Hydrocolloid dressing consists of adhesives with gel-forming components composed of either silicone or polyurethane. They are waterproof and self–adhering advanced wound care products that provide a moisture-filled healing environment for the wound. Hydrocolloid bandages are utilized for burns with moderate severity, and granular wounds and protect healed skin by absorbing moisture and swells. For instance, BenQ, a consumer electronics company, offers hydrocolloid dressing which is waterproof, invisible, and against UV rays facilitating high moisture absorption and wound healing. Major companies in the wound care devices market include Medtronic Inc., 3M Company, Smith & Nephew plc, Cardinal Health, Inc., ConvaTec Group Plc, Henry Schein, Inc., Paul Hartmann AG, Essity AB, Coloplast, and Integra Lifesciences. Asia-Pacific was the largest region in the global wound care devices market in 2022. North America was the second largest region in the global wound care devices market. Africa. was the smallest region in the global wound care devices market. The regions covered in the wound care devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the wound care devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The wound care devices market consists of sales of instruments such as non-woven dressings, gauzes, hydrocolloids dressings, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global wound care devices market is segmented - 1) By Type: Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of prostate gland enlargement which causes blockade of urethra, the tube that carries urine from the bladder. The main products in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. A resectoscope is an endoscope that is used for surgeries on the uterus, prostate, bladder, or urethra. The device helps in extracting tissue for biopsy, removing growths, or ablating diseased or damaged tissue. The various procedure types are transurethral needle ablation (TUNA), transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery, and others. The various end-users involved are hospitals, ambulatory surgical centres (ASC), clinics, homes. The benign prostatic hyperplasia (BPH) treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia (BPH) treatment market statistics, including benign prostatic hyperplasia (BPH) treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia (BPH) treatment market share, detailed benign prostatic hyperplasia (BPH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia (BPH) treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market size will grow from $1.49 billion in 2022 to $1.62 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global benign prostatic hyperplasia (BPH) market size is expected to grow to $2.09 billion in 2027 at a CAGR of 6.6%. Benign Prostatic Hyperplasia (BPH) also called Prostate Gland Enlargement (PGE), is a condition where the patient suffers from uncomfortable urinary symptoms. Due to the rising prevalence of Benign Prostatic Hyperplasia (BPH), demand for the BPH treatment devices and equipment is on a steady rise as the number of BPH cases increases the demand for devices will also increase. For example, in 2021, more than 14 million men in the United States have symptoms of BPH. Globally 30 million men have symptoms related to BPH. Therefore, with the number of BPH cases on the steady rise, the demand for BPH treatment devices and equipment is also expected to grow. The side effects suffered by the patients after a BPH procedure are one of the major restraints for the BPH device and equipment market. For example, the most common side effects of a BPH surgery include urinary incontinence, discomfort during urination, and difficulty in completely emptying the bladder. The patients suffering from BPH do not prefer surgical procedures (till the stage it can be avoided) due to these side effects, therefore decreasing the demand for surgical procedures, which in turn limits the demand for devices used by end-users like hospitals, clinics, and ambulatory surgical centres. Prostatic Artery Embolization (PAE) is one of the latest developments in the market for Benign Prostatic Hyperplasia (BPH) treatment devices and equipment. PAE is a minimally invasive treatment that assists in reducing the symptoms observed in the urinary tract. The PAE procedure is done using X-rays and other advanced imaging to observe the tumor inside the body and accordingly treat it without any surgery. This technique results in reduced complications in the treatment of BPH and thus is said to be a major development in the market of BPH treatment. Leading companies such as Boston scientific, UNC healthcare, and Spire healthcare have been investing in the market for PAE Product recall is a process of retrieving all defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and the cost of replacement. This cost of replacement for large companies can go up to a multi-million dollars, hence restraining the growth of the company and for the whole market as well. Product recall is one of the major hurdles for any market, Benign Prostatic Hyperplasia (BPH) Treatment Devices, and Equipment market is no exception. For example, in the year 2021, Arrow International recalled Arrow-Trerotola over-the-wire PTD kit percutaneous Thrombolytic device due the risk of separation. In March 2021, Olympus exercises, a Japan-based company manufacturer of optics and reprography products acquired Medi-Tate for an undisclosed amount. This acquisition of Medi-Tate to drive growth in its urology business and expand its minimally invasive treatment product portfolio. Medi-Tate is an Israeli medical device company for improves men's healthcare and quality of life through effective, non-surgical solutions. Major players in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Karl Storz, Lumenis, Olympus, Urologix, Boston Scientific Inc., Endo International, Neo tract, Lisa Laser, Medifocus Inc., ProArc Medical LTD., and Olympus America. North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2022. Western Europe was the second largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the global benign prostatic hyperplasia (BPH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The benign prostatic hyperplasia (BPH) treatment devices and equipment market consist of sales of prostatic stents, catheter ablation devices, resectoscopes, radiofrequency ablation devices, urology lasers, and prostatic stents that are used to treat benign prostatic hyperplasia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is segmented - 1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants 2) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home 3) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types

The pain management devices and therapies manage chronic and critical pain in patients suffering from various conditions, such as cancer and neurological disorder. These are mainly used for spinal cord stimulation, sacral nerve stimulators, and deep brain stimulation. The main types of pain management devices and therapies are electrical stimulators, ablation devices, neurostimulators, and analgesic pumps. The various electrical stimulation devices include transcutaneous electrical nerve stimulation (TENS) devices, neuromuscular electrical stimulation (NMES/EMS) devices, combination devices, electrotherapy devices, and TNS, ablation devices include radiofrequency ablation devices, cryoablation devices and neurostimulation devices including spinal cord stimulation (SCS) devices, deep brain stimulation devices, vagus nerve stimulation devices, and sacral nerve stimulation devices. The analgesic infusion pumps covered in this market are intrathecal infusion pumps, and external infusion pumps that are used for neuropathic pain, cancer pain, facial & migraine pain, musculoskeletal pain, and trauma applications. The pain management devices and therapies market research report is one of a series of new reports from The Business Research Company that provides pain management devices and therapies market statistics, including pain management devices and therapies industry global market size, regional shares, competitors with a pain management devices and therapies market share, detailed pain management devices and therapies market segments, market trends and opportunities, and any further data you may need to thrive in the pain management devices and therapies industry. This pain management devices and therapies market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pain management devices and therapies market grew from $4.01 billion in 2022 to $4.38 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pain management devices and therapies market is expected to grow from $6.1 billion in 2027 at a CAGR of 8.6%. An increase in demand for pain management devices due rise in chronic diseases is driving the growth of the pain management devices and therapies market. Chronic diseases such as cancer, heart stroke often lead to unbearable pain in patients and thus creating a demand for pain management drugs and therapies. Chronic diseases persist over a long period and deteriorate the health of the patient. As reported in an article by the Brazilian Journal of Nephrology, around 60% of patients with chronic kidney disease reported pain of any kind of intensity, which required pain management drugs. Similarly, according to a report in the 'US National Library of Medicine, approximately 45% or 133 million of all Americans suffered from at least one chronic disease. It is also stated that more than two-thirds of all deaths are due to one of the chronic illnesses, which included coronary heart sickness, cancer, stroke, persistent obstructive pulmonary disease, and diabetes. This rise in chronic diseases is increasing the demand for pain management devices and therapies and driving the market. The availability of other alternatives to manage pain is restraining the growth of the pain management devices and therapies market. Alternatives treatment methods such as acupuncture, Marijuana treatment, dietary supplements, vitamins, etc. are being used instead of expensive pain relief devices and equipment. These alternative treatments may help with pain from bad backs, osteoarthritis, and headaches. For instance, the use of acupuncture works well for pain caused by many conditions, including fibromyalgia, osteoarthritis, back injuries, and sports injuries. Acupuncture is an ancient Chinese treatment that involves inserting thin pins through a person's skin at specific points on the body. Acupuncture comes with no prominent side effects and costs less compared to devices and equipment used to control pain. This rise in the use of alternative treatment methods is affecting the sales of pain management devices and therapies, and limiting the growth of the market. Companies in the pain management devices and therapies industry are focusing on the use of advanced technologies to cure chronic and acute pain without the use of any opioids (drugs). Special pain relief wearable devices are being developed by several companies that can be controlled manually or through a smartphone. These devices work by gathering neural pulses from the brain which triggers the release of the body's natural pain blocker. Thus, the devices electrically stimulate the nervous system and increase the body's resistance to pain. Companies such as NeuroMetrix, Sana, Oska wellness have introduced various types of wearable devices, ranging from a wearable mask, knee band, wrist band, etc. FDA has approved these devices as OTC (over-the-counter), which can be bought without a prescription. USFDA has defined the Pain Management Devices in section 882 under the medical devices market, under subchapter-H in Code of Federal Regulations (Title 21). Under these regulations, FDA requires the device manufacturers to register and list their devices with FDA and to follow general control requirements related to labeling, packaging, performance standards, and pre-market approval. To apply for premarket approval by FDA, the manufacturer is required to submit a premarket approval application that should include evidence providing reasonable assurance that the device is safe and effective. As per the FDA rule, the manufacturer can also submit a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. Major players in the pain management devices and therapies market are Abbott Laboratories, AstraZeneca, Pfizer, Boston Scientific Corporation, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Ltd., Medtronic PLC., Novartis AG, Baxter International Inc., and Johnson & Johnson. North America was the largest region in the pain management devices and therapies market in 2022. Western Europe was the second largest region in the global pain management devices and therapies market report. The regions covered in the global pain management devices and therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pain management devices and therapies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pain management devices and therapies market consists of sales of physical therapy, massage, acupuncture, osteopathic manipulative treatment (OMT) and chiropractic adjustments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pain management devices and therapies market is segmented - 1) By Type: Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps 2) By Application: Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma 3) By Electrical Stimulation Devices: Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS 4) By Ablation Devices: Radiofrequency Ablation Devices, Cryoablation Devices 5) By Analgesic Infusion Pumps: Intrathecal Infusion Pumps, External Infusion Pumps 6) By Neurostimulation Devices: Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices

Defibrillator devices and equipment are used in the emergency treatment of life-threatening cardiac arrhythmias and abnormal heart rhythms by giving a high-energy electrical shock to the heart through the chest wall to restore its normal rhythm function. The main types of defibrillator devices and equipment are implantable defibrillators and external defibrillators. Implantable defibrillators are small, battery-powered devices placed in the body for the purpose of detecting and stopping irregular heartbeats. The implantable defibrillators are transvenous implantable cardioverter-defibrillator (T-ICDS), subcutaneous implantable cardioverter-defibrillator (S-ICDS), cardiac resynchronization therapy-defibrillator (CRT-D), single & dual chamber. The external defibrillators are manual external defibrillators (MEDs), automated external defibrillators (AEDs), and wearable cardioverter defibrillators (WCDs). The various end-users are hospitals, pre-hospitals, the public access market, the alternate care market, and home healthcare. The defibrillator devices and equipment market research report is one of a series of new reports from The Business Research Company that provides defibrillator devices and equipment market statistics, including defibrillator devices and equipment industry global market size, regional shares, competitors with a defibrillator devices and equipment market share, detailed defibrillator devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the defibrillator devices and equipment industry. This defibrillator devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global defibrillator devices and equipment market size will grow from $9.75 billion in 2022 to $10.61 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The defibrillator devices and equipment market size is expected to grow to $14.12 billion in 2027 at a CAGR of 7.4%. The rising incidence of sudden cardiac arrest (SCA) is one of the major drivers of the defibrillator devices and equipment market. According to the American Heart Association (AHA), the annual incidence of SCA in people of any age is around 356,461. SCA is characterized by the complete cessation of cardiac activity and defibrillators are used to deliver a therapeutic shock to the patient to revive the heartbeat. Due to this, the market for defibrillators is forecasted to grow. The high cost of these devices is impeding the growth of the defibrillator market. In the USA, the health care costs for administering therapeutic shock using implantable cardioverter-defibrillator (ICD) range between about $1,300 and $20,000 per patient for outpatient and inpatient care. Apart from healthcare costs, other charges such as maintenance cost, battery replacement cost, and annual servicing charges are also added to the overall cost. For instance, if AED (Automatic External Defibrillator) is used on a person suffering from a sudden cardiac arrest, then it will need to undergo maintenance before it can be used again. This includes service and the replacement of batteries and pads. Owing to these economic factors, the growth of the overall market for defibrillator devices and equipment is restrained. Technological advances are one of the major trends being witnessed in the defibrillator and equipment market. Over the last three decades, AEDs (Automated External Defibrillators) have been upgraded with several new features such as rechargeable batteries, LCD screens, voice prompts, CPR tutorials, sophisticated self-testing software, fully automatic operation, and new types of shocks. There have been several recent advancements in implantable cardioverter-defibrillator (ICD) technology to extend battery life, improvements in patient monitoring to avoid needless shocks, the introduction of quadripolar lead devices to improve device programming and to improve therapy effectiveness, and the development of magnetic resonance imaging (MRI)-safe ICDs. Defibrillators are subjected to stricter regulations by USFDA when compared to other devices. For instance, the US FDA ordered the PMA approval for new and existing automated external defibrillators. Due to manufacturing issues, the FDA has recalled more than 2 million devices since 2005. Major players in the defibrillator devices and equipment market are Medtronic, St. Jude Medical LLC., Boston Scientific Corporation, Koninklijke Philips N.V, ZOLL Medical Corporation, Cardiac Science, Physio-Control Inc., Nihon Kohden Corporation, Defibtech LLC., and Schiller AG. North America was the largest region in the global defibrillator devices and equipment market in 2022. Western Europe was the second-largest region in the defibrillator devices and equipment market. The regions covered in the global defibrillator devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the defibrillator devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The defibrillator devices and equipment market consist of sales of instruments such as manual external defibrillator, implantable cardioverter defibrillator, manual internal defibrillator, automated external defibrillator, and wearable defibrillators. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global defibrillator devices and equipment market is segmented - 1) By Type: Implantable Defibrillators, External defibrillators 2) By Implantable Defibrillators: Transvenous Implantable Cardioverter Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs), Cardiac Resynchronization Therapy- Defibrillator (CRT-D), Single & Dual Chamber 3) By External defibrillators: Manual External Defibrillator (MEDs), Automated External Defibrillator (AEDs), Wearable Cardioverter Defibrillator (WCDs) 4) By End User: Hospitals, Pre-Hospitals, Public Access Market, Alternate Care Market, Home Healthcare

Cardiac rhythm management (CRM) devices and equipment are used to manage the heart rate or rhythm by generating electrical impulses or shocks in order to get the heart back to its normal functions. CRM devices are used to treat and manage arrhythmia-related diseases such as cardiac arrests, heart failure, or cardiac arrhythmias. The main products of cardiac rhythm management devices and equipment are pacemakers, defibrillators, and cardiac resynchronization therapy (CRT). A pacemaker is a small device that's placed in the chest to control the heartbeat. It's used to prevent the heart from beating too slowly. The defibrillators are implantable cardioverter defibrillators and external defibrillators. Cardiac resynchronization therapy (CRT) includes CRT-defibrillators (CRT-D), CRT-pacemakers (CRT-P). There are implantable pacemakers and external pacemakers. The applications involved are bradycardia, tachycardia, heart failure, and others that are used by various end-users such as hospitals, ambulatory surgical centres, and physician’s clinics. The cardiac rhythm management (CRM) devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac rhythm management (CRM) devices and equipment market statistics, including cardiac rhythm management (CRM) devices and equipment industry global market size, regional shares, competitors with a cardiac rhythm management (CRM) devices and equipment market share, detailed cardiac rhythm management (CRM) devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac rhythm management (CRM) devices and equipment industry. This cardiac rhythm management (CRM) devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac rhythm management (CRM) devices and equipment market size will grow from $15.13 billion in 2022 to $16.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac rhythm management (CRM) devices and equipment market size is expected to grow to $20.05 billion in 2027 at a CAGR of 5.5%. The rising incidences of cardiovascular diseases such as cardiac arrhythmia, ischemic heart disease, and hypertension is driving the CRM devices market. Sedentary lifestyles and medical conditions such as high cholesterol, high blood pressure, obesity, and diabetes are major causes of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases account for about 31% of all global deaths. Most of these deaths occur due to heart attacks and strokes. As more people suffer from cardiovascular diseases, the demand for cardiac rhythm management and devices is expected to increase. The risks associated with cardiac rhythm management devices and equipment market is acting as a restraint on the market. CRM devices may pose potential risks such as post-implant infections and contraindications in patients undergoing any type of radiation therapy or diagnosis. Implantable CRM devices contain complementary metal-oxide-semiconductor (CMOS) which may get damaged due to therapeutic doses of radiation. Also, as the implants are highly sensitive devices, any dysfunction may have life-threatening consequences for the patients. The considerable number of risks involved in using CRM devices are affecting the growth of the market. Technologies such as subcutaneous implantable cardioverter-defibrillator (S-ICD) and leadless cardiac pacemakers (LCP) are being developed to overcome complications with transvenous lead and other CRM devices. The novel modular cardiac rhythm management (mCRM) system allows for the coordination of leadless pacing and defibrillator therapy delivery by providing wireless intra-body communication between devices. This communication is possible by a combination of anti-tachycardia pacing-enabled LCP and S ICD. For instance, Medtronic developed the leadless pacemaker Micra which can be placed in the heart through veins and is self-contained within the heart. Manufacturers of cardiac rhythm management devices and equipment are governed by various regulatory bodies such as the FDA in the USA. The United States Food and Drug Administration recalls any product with safety issues or defects that can endanger the consumer. The FDA recalled the Platinium implantable cardiac defibrillator and resynchronization therapy defibrillator due to issues with hardware configuration and functioning. The company had to discard all non-implanted Platinium devices and follow up with all patients implanted with these devices. Major players in the cardiac rhythm management (CRM) devices and equipment market are Abbott, Medtronic, Biotronik, Cardiac Science Corporation, Schiller AG, Hill-Rom Holdings Inc., GE Healthcare, Integer, Biotelemetry, and Neovasc. North America was the largest region in the global cardiac rhythm management (CRM) devices and equipment market in 2022. Western Europe was the second-largest region in the cardiac rhythm management (CRM) devices and equipment market. The regions covered in the global cardiac rhythm management (CRM) devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac rhythm management (CRM) devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The cardiac rhythm management (CRM) devices and equipment market consist of sales of Pacemakers, (implantable pacemakers, external pacemakers), defibrillators (implantable cardioverter defibrillators, external defibrillators), and cardiac resynchronization therapy (CRT-defibrillators, CRT-pacemakers) that are used for rhythm management. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac rhythm management (CRM) devices and equipment market is segmented - 1) By Product: Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) 2) By End User: Hospitals, Ambulatory surgical centers, Physicians Clinics 3) By Application: Bradycardia, Tachycardia, Heart Failure, Other Applications 4) By Pacemakers: Implantable Pacemakers, External Pacemakers 5) By Defibrillators: Implantable Cardioverter Defibrillators, External Defibrillator 6) By Cardiac Resynchronization Therapy (CRT): CRT-Defibrillators (CRT-D), CRT-Pacemakers (CRT-P)

Orthrobiologic devices are implants composed of cells and proteins that are naturally found in the human body and that provide accelerated healing by stimulating efficient regrowth of musculoskeletal tissues, including bones, cartilage, tendons, and ligaments. The main product types of orthobiologics devices and equipment are demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and synthetic orthobiologics. Stem cell therapy is promoting the repair response of diseased, dysfunctional, or injured tissue using stem cells or their derivatives. The various applications involved are osteoarthritis and degenerative arthritis, soft-tissue injuries, fracture recovery, maxillofacial and dental applications, spinal fusion, trauma repair, and reconstructive surgery that are used by various end-users such as hospitals, orthopedic clinics, and others. The orthobiologics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides orthobiologics devices and equipment market statistics, including orthobiologics devices and equipment industry global market size, regional shares, competitors with a orthobiologics devices and equipment market share, detailed orthobiologics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the orthobiologics devices and equipment industry. This orthobiologics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global othobiologics devices and equipment market grew from $4.86 billion in 2022 to $5.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The othobiologics devices and equipment market is expected to grow from $6.85 billion in 2027 at a CAGR of 6.7%. The aging population profile of most countries contributed to the growth of orthobiologics devices and equipment market globally. According to the United Nations report, there were 962 million people aged over 60 across the globe, comprising 13% of the global population. The population aged over 60 is expected to grow at a rate of about 3% every year. The report further estimated that Europe had the highest percentage of the population aged over 60. The number of people globally over the age of 65 grew by 33%, according to estimates based on Population Reference Bureau data. The increase in the aging population has increased the patient pool of many orthopedic disorders and led to an increase in the demand for orthobiologics devices and equipment market. Rising incidences of post-surgical complications in patients implanted with orthobiologics devices are one of the major restraints in the orthobiologics devices and equipment market. Surgical procedures with orthobiologics grafts, implants, and devices have become increasingly common in recent years. Major postoperative complications include device failures, bleeding, postoperative infections, immune responses, and rejections. These procedures may develop post-surgery complications which refer to the development of any unwanted or unexpected conditions related to the device, graft, or implant. These complications may vary with the type of procedure, implant, graft, or device, the experience of the surgeon, improper device testing procedures before market launch, device location in the body, and the health and biological response of the individual. The increasing post-operative complications and device failures can limit the orthobiologics devices and equipment market. Biodegradable implants are increasingly being used in orthobiologics treatment and trauma orthopedic surgeries. Biodegradable implants are used to replace a missing biological structure, support a damaged biological structure, and enhance the existing bone structure. Biodegradable products such as re-absorbable polymers composed of polyglycolic acid and polylactic acid manufactured in the form of plates, screws, and pins are replacing traditional devices like plates and screws which are more expensive. Surgeons are preferring biodegradable implants to replace conventional implants, as biodegradable implants can be engineered to provide temporary support for bone fractures, can degrade at a rate matching new tissue formation, eliminate the need for the second surgery, and are highly useful in fracture fixation in children with less implant-related infections. For instance, Stryker Corp. offers orthobiologics such as bone repair biodegradable products that are used in bone regeneration and bone healing, soft tissue regeneration, and muscle connection to bone Regulatory changes are likely to lead to increased costs relating to new product development and supply of orthobiologics devices. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. In November 2017, the USFDA has announced a comprehensive regenerative medicine policy framework to facilitate innovation. This policy deals with the manufacture of tissues, human cells, and cellular and tissue-based products other procedures to prevent the introduction, transmission, and spread of communicable diseases. Orthobiologics such as stem cell therapies are approved through this framework. The potential loss of revenue due to delays in product release, additional costs incurred by the time-consuming approval processes, and changing regulations puts a strain on investments relating to orthobiologics devices development. Major players in the orthobiologics devices and equipment market are Medtronic, Arthrex Inc., DePuy Synthes (A Subsidiary of Johnson & Johnson), Stryker Corporation, Zimmer Biomet, Bioventus LLC., Baxter International Inc., Integra Lifesciences Holding Corporation, Nuvasive Inc., and Sanofi. North America was the largest region in the global orthobiologics devices and equipment market in 2022. Western Europe was the second-largest region in the orthobiologics devices and equipment market. The regions covered in global orthobiologics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The counties covered in the orthobiologics devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The orthrobiologic devices market consists of sales of demineralized bone matrix, synthetic bone substitutes, stem cell therapy, plasma-rich protein, viscosupplementation, bone morphogenetic protein, and other synthetic orthobiologics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global orthobiologics devices and equipment market is segmented - 1) By Product Type: Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics 2) By Application: Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery 3) By End Use: Hospitals, Orthopedic Clinics, Other End Users

Transdermal skin patches refer to a drug delivery technique where a pre-prescribed dose of medication is applied as an adhesive patch and absorbed via the skin into the bloodstream. They deliver a precise, pre-set dosage of medication that is absorbed into the bloodstream through the skin. The main types of transdermal skin patches are fentanyl transdermal patches, nicotine transdermal patches, buprenorphine transdermal patches, clonidine transdermal patches, oxybutynin transdermal patches, and others. Nicotine transdermal skin patches are used to assist people in quitting smoking. They provide a source of nicotine through the skin of the human body that helps to alleviate the withdrawal symptoms associated with quitting smoking. The various products used involve a matrix, drugs in the adhesive, reservoir, and vapor that are utilised for pain relief, nicotine cessation, hormone replacement therapy, neurological disorders, cardiovascular disorders, and others. The transdermal skin patches market research report is one of a series of new reports from The Business Research Company that provides transdermal skin patches market statistics, including transdermal skin patches industry global market size, regional shares, competitors with a transdermal skin patches market share, detailed transdermal skin patches market segments, market trends and opportunities, and any further data you may need to thrive in the transdermal skin patches industry. This transdermal skin patches market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global transdermal skin patches market grew from $7.1 billion in 2022 to $7.42 billion in 2023 at a compound annual growth rate (CAGR) of 4.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The transdermal skin patches market is expected to grow from $8.43 billion in 2027 at a CAGR of 3.2%. The advances in modern technologies contribute to the growth of the transdermal skin patches market. Advances in modern technologies increase the number of drugs being delivered transdermally including small molecule hydrophobic drugs, hydrophilic drugs, and macromolecules. The new technological advances add to the increased efficiency and increased use of transdermal drug delivery systems (TDDS) thus, increasing the popularity and demand for TDDS. For instance, in September 2022, Corium, a US-based biopharmaceutical company, launched Adlarity, a transdermal patch for treating Alzheimer’s. It is a donepezil transdermal system that distributes donepezil at regular intervals through the skin. It treats people with Alzheimer's-related dementia that is mild, moderate, or severe. Adlarity makes use of the unique Corplex technology from Corium. Over a predetermined period of time, Corplex provides continuous, controlled, and sustained medication release. Stringent regulatory approval by the government regulatory bodies is a key factor hindering the growth of the transdermal skin patches market. The regulatory authority enforces the laws regulating biologics, medications, and medical devices, which can have potential side effects for customers. For instance, Food and Drug Administration (FDA) mandates the TDDS to undergo a series of tests including biomechanical testing, animal testing, and clinical trials before approving the TDDS for use in the market. The whole process consumes time and may result in a delay for the launch of TDDS into the market losing the first-mover advantage thus restraining the growth of the transdermal skin patch market. Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand their footprint for the growth of the transdermal skin patches market. The strategic merger and acquisition and collaboration followed by the players in the transdermal skin patches market allow the companies to take technological advantage by acquiring the technology which allows them to get ahead in the competition. For instance, in December 2021, Boyd Corporation, a US-based provider of advanced sealing, thermal management and protection solutions, acquired MBK Tape Solutions for an undisclosed amount. The acquisition enhances Boyd's medical material science expertise in applications including biosensors, transdermal patches, and improved wound care. MBK Tape Solutions is a US-based manufacturer of medical-grade adhesives designed for medical devices, direct wound sealing, or transdermal patches. In June 2020, Nutriband Inc., a USA-based pharmaceutical and healthcare provider that focuses on transdermal and topical technologies, acquired 4P Therapeutics Inc. for an undisclosed amount. Through the acquisition, Nutriband aimed to expand its product portfolio to include transdermal technologies, prescription drugs, and clinical development. 4P Therapeutics Inc. is a U.S.-based biotechnology healthcare research and development company that focuses on novel methods for drug delivery. Major players in the transdermal skin patches market are Mylan Pharmaceuticals Inc., Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan, Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Teva, ProSolus Inc., Medipatch Inc., AdhexPharma, Medherant Limited, Nitto Denko, Noven Pharmaceuticals, 3M Pharmaceuticals, Accrux Ltd., Access Pharmaceuticals Inc., Luye Pharma Group Ltd., Purdue Pharma L.P., Abbott Laboratories, Aneva Drug Delivery Systems, Allergan PLC., Corium International Inc., Immune Pharmaceuticals, Hercon Pharmaceuticals, Pocono and DURECT Corporation. North America was the largest region in the global transdermal skin patches market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global transdermal skin patches market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. The countries covered in the transdermal skin patches market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The transdermal skin patches market consists of sales of single-layer drug-in-adhesive, multi-layer drug-in-adhesive, and vapour patch. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global transdermal skin patches market is segmented - 1) By Product: Matrix, Drug In Adhesive, Reservoir, Vapor 2) By Type: Fentanyl Transdermal Patch, Nicotine Transdermal Patch, Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Oxybutynin Transdermal Patch, Other Types 3) By Application: Pain Relief, Nicotine Cessation, Hormone Replacement Therapy, Neurological Disorders, Cardiovascular Disorders, Other Applications

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism.It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes. The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global convalescent plasma therapy market size will grow from $0.04 billion in 2022 to $0.05 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global convalescent plasma therapy market size is expected to grow from $0.07 billion in 2027 at a CAGR of 12.0%. Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period. Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate. In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA will be observed. The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth. The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities. Different government authorities like the US FDA, CDSCO of India, and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication. In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access, and single-patient emergency only. Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition. COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications. The manufacturing process and shelf life should be the same as that of other similar plasma products. These strict guidelines framed by authorities are expected to limit the market growth. The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market. Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient. Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy. In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus. In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth. In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies. Under this collaboration, Grifols will collect plasma from FDA-approved plasma collection centres to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue). FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for public use. Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited and Orthosera Kft. North America was the largest region in the convalescent plasma therapy market in 2022. Western Europe was the second largest region in the global convalescent plasma therapy market. The regions covered in the global convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global convalescent plasma therapy market is segmented - 1) By Application: Prophylaxis, Treatment 2) By End-Users: Hospitals & Clinics, Laboratories & Research institutes 3) By Antibody type: IgM, IgG, IgA